Phase II Study of Single/Repeated Doses of Acumapimod (BCT197) to Treat Acute Exacerbations of COPD

Abstract

Mitogen-activated protein kinase p38 is a key regulator in the inflammation pathway and is activated in the lungs of chronic obstructive pulmonary disease (COPD) patients. Acumapimod is a potent, selective, oral, p38 inhibitor under investigation for treatment of acute exacerbations of COPD (AECOPD). In this Phase II, double-blind, randomized, placebo-controlled dose-exploration study of acumapimod in patients with moderate or severe AECOPD (NCT01332097), patients presenting with AECOPD were randomized to receive single-dose acumapimod (20 mg or 75 mg) on Day 1, repeated single-dose acumapimod (20 mg or 75 mg) on Days 1 and 6, oral prednisone 40 mg (10 days), or placebo. Primary outcome: improvement in forced expiratory volume in 1 s (FEV₁) versus placebo at Day 5 (single doses) and Day 10 (repeated doses). <i>N</i> = 183 patients were randomized; 169 (92%) patients completed the study. Although the primary endpoint (FEV₁ at Day 10) was not met (<i>p</i> = 0.082), there was a significant improvement in FEV₁ with acumapimod repeat-dose 75 mg versus placebo at Day 8 (<i>p</i> = 0.022) which, though not a prespecified endpoint, was part of an overall trend. Differences at lower doses did not achieve significance. Mean change in FEV₁ AUC from baseline to Day 14 in the 75 mg repeat-dose group was significantly higher versus placebo (<i>p</i> = 0.02), prednisone (<i>p</i> = 0.01), and 20 mg single-dose groups (<i>p</i> = 0.015) (post-hoc analysis). EXACT-PRO showed numerical differences versus placebo that did not reach significance. Acumapimod was well tolerated. In conclusion, repeated single-dose acumapimod showed a clinically relevant improvement in FEV₁ over placebo at Day 8, along with consistent numerical differences in EXACT-PRO. These data can be used to determine dose regimens for a proof-of-clinical-concept trial.